Guardant Health price target lowered to $65 from $75 at JPMorgan

JPMorgan lowered the firm’s price target on Guardant Health to $65 from $75 and keeps an Overweight rating on the shares. The company reported solid Q4 results and the guidance reflects conservatism, the analyst tells investors in a research note. The firm modestly lowered near-term revenue estimates but says Guardant’s long-term prospects remain unchanged.